<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H570A8E5F20024145A2320DBA5E212C9D" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 1353 IH: Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-03-13</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress>114th CONGRESS</congress> <session>1st Session</session> 
<legis-num>H. R. 1353</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20150313">March 13, 2015</action-date> 
<action-desc><sponsor name-id="B001257">Mr. Bilirakis</sponsor> (for himself, <cosponsor name-id="C001078">Mr. Connolly</cosponsor>, <cosponsor name-id="I000057">Mr. Israel</cosponsor>, and <cosponsor name-id="G000568">Mr. Griffith</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc> 
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To amend the Federal Food, Drug, and Cosmetic Act to extend the period of exclusivity with respect to certain drugs, and for other purposes.</official-title> 
</form> 
<legis-body id="HF96C51D71AAA47BF850B2760C0FCEA6F" style="OLC"> 
<section id="HC43C1DF531A34655B8308E7CE3FA6975" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015</short-title></quote>, or the <quote><short-title>PATIENT Act of 2015</short-title></quote>.</text></section> <section id="HF9B96A9D461F411FAC590AB4D17A5018"><enum>2.</enum><header>Extended exclusivity period for certain new drug applications and abbreviated new drug applications</header> <subsection id="HC2FD2248FB3C407EADEE66F0DABF096A"><enum>(a)</enum><header>New drug applications</header><text>Section 505(c)(3)(E) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(c)(3)(E)</external-xref>) is amended by adding at the end the following new clause: </text> 
<quoted-block style="OLC" id="HB6291CE9229448A487B5B09E35E8CA28" display-inline="no-display-inline"> 
<clause id="H841410200D8C4C439C3938B774B90B9F" indent="up2"><enum>(vi)</enum><text display-inline="yes-display-inline">With respect to an application described in clause (iii) or a supplement to an application described in clause (iv), the three-year period specified in such clause shall be extended for an additional 24-month period if the person submitting such application or supplement provides documentation to the Secretary demonstrating that—</text> <subclause id="H8C5DEDBAA7DC452FB356EF429BE660FA"><enum>(I)</enum><text display-inline="yes-display-inline">the new clinical investigations essential to the approval of the application or supplement and conducted or sponsored by the person submitting the application or supplement support the approval of a new indication or use for the drug that is the subject of the application or supplement; or</text></subclause> 
<subclause id="H348B7D76CB6C47A8AE52F8264440B962"><enum>(II)</enum><text display-inline="yes-display-inline">the drug that is the subject of the application or supplement has been reformulated or redesigned so that the drug can reasonably (as determined by the Secretary in consultation with the person submitting such application or supplement) be expected—</text> <item id="HE3CF28A2850E44E5ACA65451432C9551"><enum>(aa)</enum><text>to promote greater patient adherence to an approved treatment regime relative to the previously approved formulation or design of the drug;</text></item> 
<item id="H7369E7F1FDC84DA4ADBE9712F4084BFB"><enum>(bb)</enum><text>to reduce the public-health risks associated with the drug relative to the previously approved formulation or design of the drug;</text></item> <item id="H1FB76DABFF4A405E81A1DFD26F6D4C6F"><enum>(cc)</enum><text>to reduce the manner or extent of side effects or adverse events associated with the previously approved formulation or design of the drug;</text></item> 
<item id="H00EA67CC74094BE2825576CF1A1AF8A1"><enum>(dd)</enum><text>to provide systemic benefits to the health-care system relative to the previously approved formulation or design of the drug; or</text></item> <item id="HDC6B940DDF164F99AC21DBBB9CEA1C0F"><enum>(ee)</enum><text display-inline="yes-display-inline">to provide other patient benefits that are comparable to the benefits described in items (aa) through (dd).</text></item></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="H6A2EB5CE70214929B2E49D28C5609EE7"><enum>(b)</enum><header>Abbreviated new drug applications</header><text>Section 505(j)(5)(F) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(5)(F)</external-xref>) is amended by adding at the end the following new clause: </text> <quoted-block style="OLC" id="H25393CC3182D4AC3B20FF8FE98D92B88" display-inline="no-display-inline"> <clause id="H0C111A7639A844D0AAC484BB5CBF4774" indent="up3"><enum>(vi)</enum><text display-inline="yes-display-inline">With respect to an application described in clause (iii) or a supplement to an application described in clause (iv), the three-year period specified in such clause shall be extended for an additional 24-month period if the person submitting such application or supplement provides documentation to the Secretary demonstrating that—</text> 
<subclause id="HFCE99B1FA38A4EBCBEAB026085911B3D"><enum>(I)</enum><text display-inline="yes-display-inline">the new clinical investigations essential to the approval of the application or supplement and conducted or sponsored by the person submitting the application or supplement support the approval of a new indication or use for the drug that is the subject of the application or supplement; or</text></subclause> <subclause id="H8E76F50302E14BCAB9AB059438A1CA5B"><enum>(II)</enum><text display-inline="yes-display-inline">the drug that is the subject of the application or supplement has been reformulated or redesigned so that the drug may reasonably (as determined by the Secretary in consultation with the person submitting such application or supplement) be expected—</text> 
<item id="H294C1E113789434395CABBED5EB0F0B4"><enum>(aa)</enum><text>to promote greater patient adherence to an approved treatment regime relative to the previously approved formulation or design of the drug;</text></item> <item id="H4029B0AD67A84FDCBB8CA7433E8EFA1D"><enum>(bb)</enum><text>to reduce the public-health risks associated with the drug relative to the previously approved formulation or design of the drug;</text></item> 
<item id="H6D1061307A5E4CF881F7CADC0F8B5CD5"><enum>(cc)</enum><text>to reduce the manner or extent of side effects or adverse events associated with the previously approved formulation or design of the drug;</text></item> <item id="H634B7FCCF74B47FDAD5BB902E468B82C"><enum>(dd)</enum><text>to provide systemic benefits to the health-care system relative to the previously approved formulation or design of the drug; or</text></item> 
<item id="HA581D6A768054A2B838EA537C73BF30A"><enum>(ee)</enum><text display-inline="yes-display-inline">to provide other patient benefits that are comparable to the benefits described in items (aa) through (dd).</text></item></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block></subsection> <subsection id="HF01BF67F6CBD454F92EE37C13E753EE4"><enum>(c)</enum><header>Regulations</header><text display-inline="yes-display-inline">Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Human Services shall promulgate final regulations to carry out the amendments made by this section, including regulations establishing a process under which the Secretary consults with persons who claim eligibility for the extension provided by clause (vi) of subsection (c)(3)(E) or (j)(5)(F) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) (as added by subsections (a) and (b)) regarding how the drug that is the subject of such a claim may reasonably be expected to provide a benefit described in item (aa), (bb), (cc), (dd), or (ee) of clause (vi)(II) of each such subsection.</text></subsection></section> 
</legis-body> 
</bill> 


